Andrea Necchi

1 month ago | urologytimes.com | Andrea Necchi |Hannah Clarke

In the following interview, Andrea Necchi, MD, shares in-depth insights into the study, “Perioperative outcomes of neoadjuvant (neoadj) TAR-200 plus cetrelimab (CET) or CET alone in patients (pts) with muscle-invasive bladder cancer (MIBC) ineligible for or refusing neoadj cisplatin-based chemotherapy (NAC),” which was presented at the 40th Annual European Association of Urology (EAU) Congress in Madrid, Spain.

Sep 30, 2024 | europeanurology.com | Roger Li |Joshua A. Linscott |James Catto |Joshua J. Meeks |Siamak Daneshmand |Bishoy M Faltas | +4 more

Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes aDepartment of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USAbDepartment of Immunology, H.

Sep 27, 2024 | onclive.com | Andrea Necchi

Andrea Necchi, MD, associate professor, oncology, Vita-Salute San Raffaele University, director, Genitourinary Medical Oncology, IRCCS San Raffaele Hospital and Scientific Institute, discusses treatment with TAR-200 by PD-L1 expression in patients with Bacillus Calmette-Guérin (BCG)-unresponsive, high-risk non–muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), as seen in an updated dataset from the phase 2 SunRISe-1 trial (NCT04640623).

Sep 26, 2024 | onclive.com | Andrea Necchi

Andrea Necchi, MD, associate professor, oncology, Vita-Salute San Raffaele University, director, Genitourinary Medical Oncology, IRCCS San Raffaele Hospital and Scientific Institute, discusses findings from the interim analysis of the phase 2 SunRise-4 trial (NCT04919512) evaluating TAR-200 plus cetrelimab in patients with muscle-invasive bladder cancer (MIBC). SunRise-4 enrolled patients with MIBC who were ineligible for or refused treatment with neoadjuvant cisplatin-based chemotherapy.

Sep 17, 2024 | targetedonc.com | Andrea Necchi

The phase 2 SunRISe-4 study (NCT04919512) evaluated the efficacy and safety of neoadjuvant TAR-200 and cetrelimab, an anti–PD-1 agent, in patients with muscle-invasive bladder cancer (MIBC).The study found that patients receiving TAR-200 and cetrelimab had significantly higher rates of pathologic complete response (pCR) compared to those receiving cetrelimab alone. Additionally, the safety profile of TAR-200 and cetrelimab was manageable.